EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pressure BioSciences's enterprise value is $29.35 Mil.
Pressure BioSciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $-15.78 Mil. Therefore, Pressure BioSciences's EV-to-EBITDA for today is -1.86.
The historical rank and industry rank for Pressure BioSciences's EV-to-EBITDA or its related term are showing as below:
PBIO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.02 Med: -2.14 Max: 7.66
Current: -1.86
During the past 13 years, the highest EV-to-EBITDA of Pressure BioSciences was 7.66. The lowest was -12.02. And the median was -2.14.
PBIO's EV-to-EBITDA is ranked worse than 100% of 496
companies
in the Medical Devices & Instruments industry
Industry Median: 15.615
vs PBIO: -1.86
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Pressure BioSciences EV-to-EBITDA Historical Data
The historical data trend for Pressure BioSciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pressure BioSciences's EV-to-EBITDA
For the Medical Devices subindustry, Pressure BioSciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pressure BioSciences's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pressure BioSciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pressure BioSciences's EV-to-EBITDA falls into.
Pressure BioSciences's current Enterprise Value is $29.35 Mil.
Pressure BioSciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pressure BioSciences's PE Ratio (TTM) for today is calculated as:
Pressure BioSciences's share price for today is $0.0042.
Pressure BioSciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.960.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Pressure BioSciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Pressure BioSciences Inc is engaged in the healthcare division. The firm is a leader in the development & sale of enabling, pressure-based platform solutions for the world-wide life sciences industry. The company has developed and patented a technology platform that can control the sample preparation process. This process, called pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels. The company is also the distributor of the Constant Systems (CS) cell disruption equipment, parts, and consumables. Its products include Barocyclers, External Pressure Calibration Device Kits, MicroTubes, HUB High-Pressure Generators, and Accessories.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PBIO has been successfully added to your 